和铂医药与大冢制药达成6.7亿美元全球战略合作,共同推进BCMAxCD3双抗HBM7020的开发与商业化,和铂医药将获得首付款及额外付款。双方未来还将探讨更多合作机会。
Source Link和铂医药与大冢制药达成6.7亿美元全球战略合作,共同推进BCMAxCD3双抗HBM7020的开发与商业化,和铂医药将获得首付款及额外付款。双方未来还将探讨更多合作机会。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.